Vildagliptin

ویلداگلیپتین

⚠ Unverified

🍽️ Alimentary Tract And MetabolismDPP-4 inhibitor

Market / country: UK

Galvus (UK)

🧮 Dose calculator

Type 2 diabetes mellitus · Regimen source: UK Galvus SmPC · 4.2

  • • Doses above 100 mg/day not recommended. In dual combination with a sulphonylurea, 50 mg once in the morning. UK Galvus SmPC · 4.2

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

Warnings

Formulations

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. UK Galvus SmPC · 4.6

    “There are no adequate data from the use of vildagliptin in pregnant women.”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. UK Galvus SmPC · 4.6

    “Animal studies have shown excretion of vildagliptin in milk.”
  • 👶 ChildrenSafety not established

    Label: safety and effectiveness in children have not been established. UK Galvus SmPC · 4.2

    “The safety and efficacy of Galvus in children and adolescents (< 18 years) have not been established.”
  • 👴 Older adultsNo specific problem stated

    Label: no specific difference or dose adjustment stated for older adults. UK Galvus SmPC · 4.2

    “Elderly (≥ 65 years) No dose adjustments are necessary in elderly patients (see also sections 5.1 and 5.2).”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Inspired by the Saphira project; part of the content is taken from it.

Contact and correction requests — Telegram: @cenaav